To the full analysis
Buyback calculator for Ligand Pharmaceuticals
Ligand Pharmaceuticals stock: key metrics
LGNDLigand Pharmaceuticals had an operating margin of 17.6% and a return on invested capital (ROIC) of 5.6% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 83.9% | −119.7% | −22.5% |
| 2007 | 100.0% | −466.7% | 2,184.6% |
| 2008 | 100.0% | −356.1% | −359.2% |
| 2009 | 60.9% | −25.6% | −5.0% |
| 2010 | 100.0% | −124.5% | −53.2% |
| 2011 | 83.7% | −2.3% | 33.9% |
| 2012 | 88.5% | 1.8% | −1.7% |
| 2013 | 88.3% | 30.5% | no data |
| 2014 | 85.8% | 30.4% | 18.6% |
| 2015 | 91.9% | 38.0% | 357.8% |
| 2016 | 94.9% | 40.3% | no data |
| 2017 | 96.2% | 48.2% | 8.9% |
| 2018 | 97.5% | 65.1% | 57.0% |
| 2019 | 90.6% | 671.0% | 523.2% |
| 2020 | 81.4% | 22.9% | no data |
| 2021 | 74.3% | 43.0% | no data |
| 2022 | 73.1% | 1.5% | no data |
| 2023 | 73.3% | 9.1% | 39.7% |
| 2024 | 93.4% | −13.5% | −2.4% |
| 2025 | 97.5% | 17.6% | 46.4% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −100.0% | −69.1% | −9.7% |
| 2007 | 200.0% | −30.0% | 162.6% |
| 2008 | 200.0% | −67.9% | −57.2% |
| 2009 | −52.0% | −9.6% | −1.7% |
| 2010 | 179.0% | −42.3% | −16.6% |
| 2011 | 117.7% | −2.5% | 8.3% |
| 2012 | −2.0% | 1.1% | −0.5% |
| 2013 | no data | 33.7% | no data |
| 2014 | 45.7% | 39.4% | 4.7% |
| 2015 | 84.5% | 15.1% | 48.2% |
| 2016 | no data | 5.8% | no data |
| 2017 | 3.0% | 7.7% | 1.9% |
| 2018 | 25.6% | 31.0% | 11.4% |
| 2019 | 82.0% | 163.4% | 42.1% |
| 2020 | no data | 6.8% | no data |
| 2021 | no data | 13.3% | no data |
| 2022 | no data | 0.2% | no data |
| 2023 | 7.4% | 2.0% | 6.6% |
| 2024 | −0.5% | −2.0% | −0.4% |
| 2025 | 12.2% | 5.6% | 8.0% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 30 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.